PURPOSE: Biomarkers of radiation-induced behavioral symptoms, such as fatigue, have not been identified. Studies linking inflammatory processes to fatigue in cancer survivors led us to test the hypothesis that activation of the proinflammatory cytokine network is associated with fatigue symptoms during radiation therapy for breast and prostate cancer. EXPERIMENTAL DESIGN: Individuals with early-stage breast (n = 28) and prostate cancer (n = 20) completed questionnaires and provided blood samples for determination of serum levels of interleukin 1beta (IL-1beta) and IL-6 at assessments conducted before, during, and after a course of radiation therapy. Serum markers of proinflammatory cytokine activity, including IL-1 receptor antagonist and C-reactive protein, were examined in a subset of participants. Random coefficient models were used to evaluate the association between changes in cytokine levels and fatigue. RESULTS: As expected, there was a significant increase in fatigue during radiation treatment. Changes in serum levels of inflammatory markers C-reactive protein and IL-1 receptor antagonist were positively associated with increases in fatigue symptoms (Ps < 0.05), although serum levels of IL-1beta and IL-6 were not associated with fatigue. These effects remained significant (Ps < 0.05) in analyses controlling for potential biobehavioral confounding factors, including age, body mass index, hormone therapy, depression, and sleep disturbance. CONCLUSIONS: Results suggest that activation of the proinflammatory cytokine network and associated increases in downstream biomarkers of proinflammatory cytokine activity are associated with fatigue during radiation therapy for breast and prostate cancer.
PURPOSE: Biomarkers of radiation-induced behavioral symptoms, such as fatigue, have not been identified. Studies linking inflammatory processes to fatigue in cancer survivors led us to test the hypothesis that activation of the proinflammatory cytokine network is associated with fatigue symptoms during radiation therapy for breast and prostate cancer. EXPERIMENTAL DESIGN: Individuals with early-stage breast (n = 28) and prostate cancer (n = 20) completed questionnaires and provided blood samples for determination of serum levels of interleukin 1beta (IL-1beta) and IL-6 at assessments conducted before, during, and after a course of radiation therapy. Serum markers of proinflammatory cytokine activity, including IL-1 receptor antagonist and C-reactive protein, were examined in a subset of participants. Random coefficient models were used to evaluate the association between changes in cytokine levels and fatigue. RESULTS: As expected, there was a significant increase in fatigue during radiation treatment. Changes in serum levels of inflammatory markers C-reactive protein and IL-1 receptor antagonist were positively associated with increases in fatigue symptoms (Ps < 0.05), although serum levels of IL-1beta and IL-6 were not associated with fatigue. These effects remained significant (Ps < 0.05) in analyses controlling for potential biobehavioral confounding factors, including age, body mass index, hormone therapy, depression, and sleep disturbance. CONCLUSIONS: Results suggest that activation of the proinflammatory cytokine network and associated increases in downstream biomarkers of proinflammatory cytokine activity are associated with fatigue during radiation therapy for breast and prostate cancer.
Authors: Luigi Ferrucci; Alessandro Ble; Stefania Bandinelli; Fulvio Lauretani; Kristen Suthers; Jack M Guralnik Journal: Aging Clin Exp Res Date: 2004-06 Impact factor: 3.636
Authors: Julienne E Bower; Patricia A Ganz; Sally S Dickerson; Laura Petersen; Najib Aziz; John L Fahey Journal: Psychoneuroendocrinology Date: 2005-01 Impact factor: 4.905
Authors: Kristine A Donovan; Paul B Jacobsen; Michael A Andrykowski; Erin M Winters; Lodovico Balducci; Uzma Malik; Daniel Kenady; Patrick McGrath Journal: J Pain Symptom Manage Date: 2004-10 Impact factor: 3.612
Authors: Christopher Wratten; Janice Kilmurray; Sharon Nash; Michael Seldon; Christopher S Hamilton; Peter C O'Brien; J W Denham Journal: Int J Radiat Oncol Biol Phys Date: 2004-05-01 Impact factor: 7.038
Authors: Jason M York; Neil A Blevins; Daryl D Meling; Molly B Peterlin; Daila S Gridley; Keith A Cengel; Gregory G Freund Journal: Brain Behav Immun Date: 2011-09-21 Impact factor: 7.217
Authors: Aaron J Grossberg; Elisabeth G Vichaya; Diana L Christian; Jessica M Molkentine; Daniel W Vermeer; Phillip S Gross; Paola D Vermeer; John H Lee; Robert Dantzer Journal: Cancer Res Date: 2017-12-07 Impact factor: 12.701
Authors: Alicia K Smith; Karen N Conneely; Thaddeus W W Pace; Donna Mister; Jennifer C Felger; Varun Kilaru; Mary J Akel; Paula M Vertino; Andrew H Miller; Mylin A Torres Journal: Brain Behav Immun Date: 2014-02-28 Impact factor: 7.217
Authors: Andrea M Barsevick; Michael R Irwin; Pamela Hinds; Andrew Miller; Ann Berger; Paul Jacobsen; Sonia Ancoli-Israel; Bryce B Reeve; Karen Mustian; Ann O'Mara; Jin-Shei Lai; Michael Fisch; David Cella Journal: J Natl Cancer Inst Date: 2013-09-18 Impact factor: 13.506
Authors: Lu Miao; Aaron K Holley; Yanming Zhao; William H St Clair; Daret K St Clair Journal: Antioxid Redox Signal Date: 2014-01-22 Impact factor: 8.401